- Δεν υπάρχουν δεδομένα
Ελληνικά
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, French femtosecond pulse and high peak power (PW class) laser manufacturer Amplitude announced that the company has launched a newly designed Satsuma X femtosecond laser, setting a new benchmark for industrial environments.This product was first announced in 2022 and is now available in a brand new design with proven durability and versatility. In pursuit of excellence and customer satis...
Recently, companies from Lithuania, Italy, and Germany have reached a new milestone in the European independent space mission - based on the Galactic project, they have developed a supply chain for Alexandrite laser crystals in Europe to study changes in the atmosphere and Earth's surface.The high-power Alexander laser crystals and coatings developed in the GALACTIC project will be used to collect...
On June 24-27, 2025, the global optoelectronic event Laser World of Photonics 2025 was grandly opened in Munich, Germany. This exhibition brings together over 1350 companies from 43 countries, making it the largest in history. Among them, international laser giants Coherent, IPG, TRUMPF, and MKS showcased their latest breakthroughs and future directions in laser technology with multiple heavyweigh...
Recently, Shao Jianda, a researcher of Shanghai Institute of Optics and Precision Mechanics, Chinese Academy of Sciences, Jin Yunxia, a researcher team, and Li Chaoyang, a researcher of Zhangjiang Laboratory, have made breakthroughs in the field of ultra wideband pulse compression gratings.The research team has successfully developed a ultra 400 nm broadband gold grating for single cycle pulse com...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...